Loading…
Sexual disorders and psychotropic drugs :about 250 cases
IntroductionThe effect of psychotropic drugs on sexuality is difficult to evaluate because psychiatric disorders are frequently accompanied by sexual dysfunction, independently of any drug intake. However, the iatrogenic aspects of psychotropic drugs linked to their side effects should not be undere...
Saved in:
Published in: | European psychiatry 2023-03, Vol.66 (S1), p.S72-S73 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | S73 |
container_issue | S1 |
container_start_page | S72 |
container_title | European psychiatry |
container_volume | 66 |
creator | tbatou, L yassmine, B fouad, L |
description | IntroductionThe effect of psychotropic drugs on sexuality is difficult to evaluate because psychiatric disorders are frequently accompanied by sexual dysfunction, independently of any drug intake. However, the iatrogenic aspects of psychotropic drugs linked to their side effects should not be underestimated since they are an important cause of treatment discontinuation.ObjectivesThe aim is to show the type of sexual impairment observed according to the different psychotropic drugs used and the means to remedy it. Psychiatric disorders are accompanied by sexual dysfunctions which can be aggravated by psychotropic drugs, and the associated risk factors can be sought or aggravate this undesirable effect.MethodsThis is a cross-sectional study, concerning patients followed at ArRazi hospital under antipsychotic treatment. We used the “International Index of Erectile Dysfunction” scale, and the data were analyzed by SPSS software.Results68% are men, Age: 71% are between 20 and 50 years old.Marital status: 43% are single, 24% are married, 34% are divorced.83% have a low socioeconomic level, 45% have a family history of a psychiatric disorder.58% of patients have a substance use disorder.38% of patients consulted for a psychotic syndrome, 23% for a depressive syndrome, 17% for a manic syndrome, 11% for a behavioral disorder, 6% for a suicide attempt.46% of the medications are antipsychotics, 18% are antidepressants, 15% are mood regulators.83% of the sexual disorder appeared in the first 5 years.72% of the patients did not receive information by their doctor about this side effect.64% of the patients informed their doctor.32% stopped the treatment, 47% asked to change the treatment.ConclusionsCareful assessment of sexual function at the initial visit followed by monitoring at subsequent visits is essential. Treatment of adverse sexual effects may be pharmacological, behavioral, complementary and integrative, or a combination of these modalitiesDisclosure of InterestNone Declared |
doi_str_mv | 10.1192/j.eurpsy.2023.239 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_999cfa1377cb49e792a71d8877a94e03</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_999cfa1377cb49e792a71d8877a94e03</doaj_id><sourcerecordid>2880496358</sourcerecordid><originalsourceid>FETCH-LOGICAL-d1508-e989505fb1ea4c2531a5f1331cad8d3133db3dc77a971fc0901c33822966a6973</originalsourceid><addsrcrecordid>eNpV0E1Lw0AQBuBFFKzVH-At4Dl1P7LZHS8ixY9CwYN6Xia7mzYh7dbdROy_N9pePM0wLzwMLyHXjM4YA37bzvwQd2k_45SLGRdwQiZMKZ0LqeUpmVDgRQ5C6HNykVJLKVOUlhOi3_z3gF3mmhSi8zFluHXZCNl16GPYNTZzcVil7A6rMPQZlzSzmHy6JGc1dslfHeeUfDw9vs9f8uXr82L-sMwdk1TnHjRIKuuKeSwsl4KhrJkQzKLTToybq4SzSiEoVlsKlNnxS86hLLEEJaZkcXBdwNbsYrPBuDcBG_N3CHFlMPaN7bwBAFsjE0rZqgCvgKNiTutfvPBUjNb9wdoN1cY767d9xO4f-j_ZNmuzCl-GUQklF3oUbo5CDJ-DT71pwxC3YwGGa00LKMe-xQ-dOHie</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2880496358</pqid></control><display><type>article</type><title>Sexual disorders and psychotropic drugs :about 250 cases</title><source>Publicly Available Content Database</source><source>Cambridge University Press</source><source>PubMed Central</source><creator>tbatou, L ; yassmine, B ; fouad, L</creator><creatorcontrib>tbatou, L ; yassmine, B ; fouad, L</creatorcontrib><description>IntroductionThe effect of psychotropic drugs on sexuality is difficult to evaluate because psychiatric disorders are frequently accompanied by sexual dysfunction, independently of any drug intake. However, the iatrogenic aspects of psychotropic drugs linked to their side effects should not be underestimated since they are an important cause of treatment discontinuation.ObjectivesThe aim is to show the type of sexual impairment observed according to the different psychotropic drugs used and the means to remedy it. Psychiatric disorders are accompanied by sexual dysfunctions which can be aggravated by psychotropic drugs, and the associated risk factors can be sought or aggravate this undesirable effect.MethodsThis is a cross-sectional study, concerning patients followed at ArRazi hospital under antipsychotic treatment. We used the “International Index of Erectile Dysfunction” scale, and the data were analyzed by SPSS software.Results68% are men, Age: 71% are between 20 and 50 years old.Marital status: 43% are single, 24% are married, 34% are divorced.83% have a low socioeconomic level, 45% have a family history of a psychiatric disorder.58% of patients have a substance use disorder.38% of patients consulted for a psychotic syndrome, 23% for a depressive syndrome, 17% for a manic syndrome, 11% for a behavioral disorder, 6% for a suicide attempt.46% of the medications are antipsychotics, 18% are antidepressants, 15% are mood regulators.83% of the sexual disorder appeared in the first 5 years.72% of the patients did not receive information by their doctor about this side effect.64% of the patients informed their doctor.32% stopped the treatment, 47% asked to change the treatment.ConclusionsCareful assessment of sexual function at the initial visit followed by monitoring at subsequent visits is essential. Treatment of adverse sexual effects may be pharmacological, behavioral, complementary and integrative, or a combination of these modalitiesDisclosure of InterestNone Declared</description><identifier>ISSN: 0924-9338</identifier><identifier>EISSN: 1778-3585</identifier><identifier>DOI: 10.1192/j.eurpsy.2023.239</identifier><language>eng</language><publisher>Paris: Cambridge University Press</publisher><subject>Abstract ; Drugs ; Erectile dysfunction ; Mental disorders ; Oral Communication ; Psychotropic drugs ; Substance abuse treatment</subject><ispartof>European psychiatry, 2023-03, Vol.66 (S1), p.S72-S73</ispartof><rights>The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association. This work is licensed under the Creative Commons Attribution License This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2023 2023 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2880496358/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2880496358?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,25734,27905,27906,36993,44571,53772,53774,74875</link.rule.ids></links><search><creatorcontrib>tbatou, L</creatorcontrib><creatorcontrib>yassmine, B</creatorcontrib><creatorcontrib>fouad, L</creatorcontrib><title>Sexual disorders and psychotropic drugs :about 250 cases</title><title>European psychiatry</title><description>IntroductionThe effect of psychotropic drugs on sexuality is difficult to evaluate because psychiatric disorders are frequently accompanied by sexual dysfunction, independently of any drug intake. However, the iatrogenic aspects of psychotropic drugs linked to their side effects should not be underestimated since they are an important cause of treatment discontinuation.ObjectivesThe aim is to show the type of sexual impairment observed according to the different psychotropic drugs used and the means to remedy it. Psychiatric disorders are accompanied by sexual dysfunctions which can be aggravated by psychotropic drugs, and the associated risk factors can be sought or aggravate this undesirable effect.MethodsThis is a cross-sectional study, concerning patients followed at ArRazi hospital under antipsychotic treatment. We used the “International Index of Erectile Dysfunction” scale, and the data were analyzed by SPSS software.Results68% are men, Age: 71% are between 20 and 50 years old.Marital status: 43% are single, 24% are married, 34% are divorced.83% have a low socioeconomic level, 45% have a family history of a psychiatric disorder.58% of patients have a substance use disorder.38% of patients consulted for a psychotic syndrome, 23% for a depressive syndrome, 17% for a manic syndrome, 11% for a behavioral disorder, 6% for a suicide attempt.46% of the medications are antipsychotics, 18% are antidepressants, 15% are mood regulators.83% of the sexual disorder appeared in the first 5 years.72% of the patients did not receive information by their doctor about this side effect.64% of the patients informed their doctor.32% stopped the treatment, 47% asked to change the treatment.ConclusionsCareful assessment of sexual function at the initial visit followed by monitoring at subsequent visits is essential. Treatment of adverse sexual effects may be pharmacological, behavioral, complementary and integrative, or a combination of these modalitiesDisclosure of InterestNone Declared</description><subject>Abstract</subject><subject>Drugs</subject><subject>Erectile dysfunction</subject><subject>Mental disorders</subject><subject>Oral Communication</subject><subject>Psychotropic drugs</subject><subject>Substance abuse treatment</subject><issn>0924-9338</issn><issn>1778-3585</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpV0E1Lw0AQBuBFFKzVH-At4Dl1P7LZHS8ixY9CwYN6Xia7mzYh7dbdROy_N9pePM0wLzwMLyHXjM4YA37bzvwQd2k_45SLGRdwQiZMKZ0LqeUpmVDgRQ5C6HNykVJLKVOUlhOi3_z3gF3mmhSi8zFluHXZCNl16GPYNTZzcVil7A6rMPQZlzSzmHy6JGc1dslfHeeUfDw9vs9f8uXr82L-sMwdk1TnHjRIKuuKeSwsl4KhrJkQzKLTToybq4SzSiEoVlsKlNnxS86hLLEEJaZkcXBdwNbsYrPBuDcBG_N3CHFlMPaN7bwBAFsjE0rZqgCvgKNiTutfvPBUjNb9wdoN1cY767d9xO4f-j_ZNmuzCl-GUQklF3oUbo5CDJ-DT71pwxC3YwGGa00LKMe-xQ-dOHie</recordid><startdate>20230301</startdate><enddate>20230301</enddate><creator>tbatou, L</creator><creator>yassmine, B</creator><creator>fouad, L</creator><general>Cambridge University Press</general><scope>3V.</scope><scope>7XB</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>M2M</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230301</creationdate><title>Sexual disorders and psychotropic drugs :about 250 cases</title><author>tbatou, L ; yassmine, B ; fouad, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d1508-e989505fb1ea4c2531a5f1331cad8d3133db3dc77a971fc0901c33822966a6973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Abstract</topic><topic>Drugs</topic><topic>Erectile dysfunction</topic><topic>Mental disorders</topic><topic>Oral Communication</topic><topic>Psychotropic drugs</topic><topic>Substance abuse treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>tbatou, L</creatorcontrib><creatorcontrib>yassmine, B</creatorcontrib><creatorcontrib>fouad, L</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Psychology Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>European psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>tbatou, L</au><au>yassmine, B</au><au>fouad, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sexual disorders and psychotropic drugs :about 250 cases</atitle><jtitle>European psychiatry</jtitle><date>2023-03-01</date><risdate>2023</risdate><volume>66</volume><issue>S1</issue><spage>S72</spage><epage>S73</epage><pages>S72-S73</pages><issn>0924-9338</issn><eissn>1778-3585</eissn><abstract>IntroductionThe effect of psychotropic drugs on sexuality is difficult to evaluate because psychiatric disorders are frequently accompanied by sexual dysfunction, independently of any drug intake. However, the iatrogenic aspects of psychotropic drugs linked to their side effects should not be underestimated since they are an important cause of treatment discontinuation.ObjectivesThe aim is to show the type of sexual impairment observed according to the different psychotropic drugs used and the means to remedy it. Psychiatric disorders are accompanied by sexual dysfunctions which can be aggravated by psychotropic drugs, and the associated risk factors can be sought or aggravate this undesirable effect.MethodsThis is a cross-sectional study, concerning patients followed at ArRazi hospital under antipsychotic treatment. We used the “International Index of Erectile Dysfunction” scale, and the data were analyzed by SPSS software.Results68% are men, Age: 71% are between 20 and 50 years old.Marital status: 43% are single, 24% are married, 34% are divorced.83% have a low socioeconomic level, 45% have a family history of a psychiatric disorder.58% of patients have a substance use disorder.38% of patients consulted for a psychotic syndrome, 23% for a depressive syndrome, 17% for a manic syndrome, 11% for a behavioral disorder, 6% for a suicide attempt.46% of the medications are antipsychotics, 18% are antidepressants, 15% are mood regulators.83% of the sexual disorder appeared in the first 5 years.72% of the patients did not receive information by their doctor about this side effect.64% of the patients informed their doctor.32% stopped the treatment, 47% asked to change the treatment.ConclusionsCareful assessment of sexual function at the initial visit followed by monitoring at subsequent visits is essential. Treatment of adverse sexual effects may be pharmacological, behavioral, complementary and integrative, or a combination of these modalitiesDisclosure of InterestNone Declared</abstract><cop>Paris</cop><pub>Cambridge University Press</pub><doi>10.1192/j.eurpsy.2023.239</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0924-9338 |
ispartof | European psychiatry, 2023-03, Vol.66 (S1), p.S72-S73 |
issn | 0924-9338 1778-3585 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_999cfa1377cb49e792a71d8877a94e03 |
source | Publicly Available Content Database; Cambridge University Press; PubMed Central |
subjects | Abstract Drugs Erectile dysfunction Mental disorders Oral Communication Psychotropic drugs Substance abuse treatment |
title | Sexual disorders and psychotropic drugs :about 250 cases |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T21%3A54%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sexual%20disorders%20and%20psychotropic%20drugs%20:about%20250%20cases&rft.jtitle=European%20psychiatry&rft.au=tbatou,%20L&rft.date=2023-03-01&rft.volume=66&rft.issue=S1&rft.spage=S72&rft.epage=S73&rft.pages=S72-S73&rft.issn=0924-9338&rft.eissn=1778-3585&rft_id=info:doi/10.1192/j.eurpsy.2023.239&rft_dat=%3Cproquest_doaj_%3E2880496358%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-d1508-e989505fb1ea4c2531a5f1331cad8d3133db3dc77a971fc0901c33822966a6973%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2880496358&rft_id=info:pmid/&rfr_iscdi=true |